Loading...
•
Mar 31, 2022
Rigel Q1 2022 Earnings Report
Rigel reported a net loss for the first quarter of 2022, with TAVALISSE sales increasing compared to the same period in 2021.
Key Takeaways
Rigel Pharmaceuticals reported a net loss of $27.4 million for the first quarter of 2022. Total revenues were $16.7 million, including $16.2 million in TAVALISSE net product sales. TAVALISSE sales increased by 31% compared to the first quarter of 2021.
Rigel delivered a solid quarter of TAVALISSE sales in ITP.
The company believes it is well positioned for increasing sales in upcoming quarters.
Phase 3 fostamatinib results from wAIHA trial are expected in mid-2022.
Addition of fostamatinib as a first-to-market therapy in wAIHA is a key next step in building a world-class hem-onc franchise.
Forward Guidance
Rigel is expecting to report Phase 3 fostamatinib results from their wAIHA trial in mid-2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...